Patrick Harrison Carroll

HIMS CMO Patrick Harrison Carroll sold 23,726 shares at $35.00 (total $830.4K); post-sale holdings 181.9K shares via scheduled 10b5-1 plan.

Patrick Harrison Carroll, Chief Medical Officer of Hims & Hers Health, Inc., executed a scheduled sale of 23,726 shares at $35.00 per share on 2026-06-18 under a pre-arranged 10b5-1 trading plan. The sale reduced his holdings by 11.5% from 205,587 shares to 181.9K shares. Since this transaction is part of a 10b5-1 plan, it is scheduled and automatic rather than a discretionary trade reflecting real-time market judgment. At current price $32.96, the stock is -53.2% from its 52-week high of $70.43, though it has appreciated 38.8% over the past 30 days and 58.2% over the past 90 days. Notably, Carroll's same-ticker history at HIMS shows mixed outcomes: his September 2025 sale was followed by -1.4% (30d) and -27.0% (90d) returns, while his August 2025 sale preceded -9.6% (30d) and -20.1% (90d) results, suggesting prior HIMS sales have not consistently aligned with subsequent stock performance. The company reported revenue of $608.1M with net income of -$92.1M in the latest quarter, alongside 59.0% annual revenue growth, indicating strong top-line momentum despite current profitability challenges.

CMO Carroll Patrick Harrison sold 10,021 shares of HIMS at $50.50 on 2025-09-17, retaining 169,940 shares.

Harrison sold 10,021 shares at $50.50 on 2025-09-17, reducing his holdings by 5.6% to 169,940 shares while the stock currently trades at $57.82. This is his third open-market sale at HIMS within six months (prior sells on 2025-08-06 and 2025-03-18), establishing a pattern of regular liquidation. His two same-ticker prior sales showed mixed outcomes: the March 2025 sale was ultimately well-timed at the 90-day mark (+74.2% outcome suggests stock rallied after entry, not after sale—context requires clarification), while the August 2025 sale occurred only 42 days prior with a -9.6% 30-day return. The company posted strong fundamentals with $544.8M latest-quarter revenue, +69.3% annual growth, and $42.5M net income, but carries an elevated P/E of 99.69, suggesting the recent 33.3% 30-day rally and current price represent peak valuation territory. The timing of this sale—following a sharp 30-day rebound but down 15.9% from the 52-week high—reflects measured exit rather than panic or conviction-driven positioning.

HIMS Chief Medical Officer sells 60,000 shares ($3.2M) at $53.58; holds 169,940 shares post-transaction

Carroll Patrick Harrison, Chief Medical Officer at HIMS, sold 60,000 shares (26.1% of prior holdings) at $53.58 on 2025-08-06, representing $3,214,878.00 in proceeds. At the current price of $51.94, the stock trades 24.4% below its 52-week high of $68.74, and Harrison's post-transaction holdings of 169,940 shares represent a material reduction in direct equity stake. His prior HIMS sale on 2025-03-18 was poorly timed relative to the 90-day window (stock rose +74.2% after), and this transaction occurs in a context where the stock has remained essentially flat over 90 days despite strong fundamental growth (annual revenue up 69.3%, net income at $42.5M). The timing and magnitude of this sale warrant monitoring against future price action, given both the senior medical leadership involved and the stock's elevated valuation (P/E of 89.55).

CMO Carroll Patrick Harrison sold 23,287 shares of HIMS at $34.31; stock down 54.2% from 52-week high at $31.49 current

Carroll Patrick Harrison, Chief Medical Officer, sold 23,287 shares (23.3K shares) at $34.31 on 2025-03-18, reducing his holdings by 10.0% to 209,661 shares (209.7K shares). The sale occurred at $34.31, a price $2.82 above the current price of $31.49, which is -54.2% from the 52-week high of $68.74. HIMS stock has declined -47.9% over the past 30 days despite strong fundamentals: latest quarterly revenue of $401,556,000.00 ($401.6M) with annual revenue growth of +69.3%, net income of $75,588,000.00 ($75.6M), and a P/E of 54.29. The CMO's sale at a historically elevated price point relative to current levels, combined with the stock's substantial recent drawdown, provides a factual data point for investors monitoring executive activity during a period of significant valuation correction.